Skip to navigation bar Skip to breadcrumbs Skip to page content
Envelope icon E-mail Updates Teal square Text size:  a A A
You are here: HomeAnnouncementsAnnouncement Detail

Final Recommendation Statement: Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia

The U.S. Preventive Services Task Force released today a final recommendation statement on low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia. To view the recommendation and the evidence on which it is based, please go to http://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/low-dose-aspirin-use-for-the-prevention-of-morbidity-and-mortality-from-preeclampsia-preventive-medication. A fact sheet that explains the final recommendation in plain language is also available. The final recommendation statement can also be found in the September 9 online issue of Annals of Internal Medicine.

Current as of: December 2017

Internet Citation: Final Recommendation Statement: Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia. U.S. Preventive Services Task Force. September 2014.
https://www.uspreventiveservicestaskforce.org/Announcements/News/Item/final-recommendation-statement-low-dose-aspirin-use-for-the-prevention-of-morbidity-and-mortality-from-preeclampsia

USPSTF Program Office   5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857